Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis.
It has been reported that when 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors are utilized for treatment of hypercholesterolemia, as much as 50% inhibition of whole body cholesterol biosynthesis is observed. As general inhibitors of isoprenoid biosynthesis, these compounds can also inhibit the synthesis of the substituents of isoprenylated proteins. For two mammalian proteins (p21ras and lamin A), it has been demonstrated that such inhibition of biosynthesis of the isoprenoid substituent blocks proteolytic maturation of these proteins. It has been argued that advantage may be taken of this phenomenon to block the synthesis of p21ras in malignancies. It is also possible that treatment of hypercholesterolemia with lovastatin might produce problematic inhibition of protein processing dependent upon isoprenylation. In this report, we compare the concentration dependence of inhibition of isoprenylation dependent protein processing and sterol biosynthesis. Effects of partial inhibition of isoprenylated protein processing on whole cells can be sensitively assessed by visualization of lamina structure through indirect immunofluorescence. Our results indicate that the degree of inhibition of p21ras and prelamin A maturation by lovastatin is identical. Thus, 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors are unlikely to be useful as anti-malignancy drugs. However, the conditions of lovastatin treatment which produce 50% inhibition of sterol biosynthesis analogous to pharmacological conditions, produce no observable effects on isoprenylated protein maturation.
Sinensky
M
M
Eleanor Roosevelt Institute for Cancer Research, Denver, Colorado 80206.
Beck
L A
LA
Leonard
S
S
Evans
R
R
D000818:Animals; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D002784:Cholesterol / Q000096:biosynthesis*; D006224:Cricetinae; D005455:Fluorescent Antibody Technique; D006367:HeLa Cells; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D034904:Lamin Type A; D034882:Lamins; D008148:Lovastatin / Q000494:pharmacology*; D009687:Nuclear Proteins / Q000378:metabolism; D015689:Oncogene Protein p21(ras) / Q000378:metabolism; D011106:Polyisoprenyl Phosphates / Q000378:metabolism*; D011499:Protein Processing, Post-Translational / Q000187:drug effects*; D011506:Proteins / Q000378:metabolism*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D034904:Lamin Type A; D034882:Lamins; D009687:Nuclear Proteins; D011106:Polyisoprenyl Phosphates; D011506:Proteins; D002784:Cholesterol; D008148:Lovastatin; D015689:Oncogene Protein p21(ras)